摘要
目的观察替格瑞洛在冠心病冠脉介入治疗后的安全性。方法选取2015年1~12月期间在我院进行治疗的50例冠心病冠脉介入治疗后患者作为研究对象,根据临床治疗方案的不同分为两组,其中对照组25例患者采用阿司匹林肠溶片+氯吡格雷双抗血小板进行治疗,观察组25例患者采用替格瑞洛+阿司匹林肠溶片双抗血小板进行治疗。比较两治疗组患者的临床治疗效果、心血管不良事件(MACE)及不良反应发生率。结果研究组有效率为96%,对照组为92%,差异无统计学意义(P>0.05);研究组的MACE发生率为8%,对照组为8%,差异无统计学意义(P>0.05);研究组的不良反应发生率为12%,对照组为12%,差异无统计学意义(P>0.05)。结论替格瑞洛在冠脉介入治疗后的临床使用治疗效果与氯吡格雷无明显的差别,心血管不良事件(MACE)发生率无明显的差别。出血不良反应无明显的差别,但观察中替格瑞洛发生呼吸困难的1例。
Objective To observe the safety of the treatment of coronary heart disease （CHD） after percutaneous coronary intervention （PCI）. Methods 50 cases of coronary artery interventional therapy after treatment of patients in our hospital from January 2015 to December 2015 were selected as the research object.They were divided into two groups according to different clinical treatment.Patients in the control group （25 cases） were treated with Aspirin Enteric-coated Tablets＋clopidogrel dual antiplatelet therapy,and patients in the study group （25 cases） were treated with ticagrelor Aspirin Enteric-coated Tablets＋dual antiplatelet therapy.The clinical therapeutic effect,adverse cardiovascular events （MACE） and adverse reactions were compared between the two groups. Results The effective rate of study group was 96%,which was 92% in the control group,and the difference was not statistically significant （P ~ 0.05）.The incidence rate of MACE of study group was 8%,which was 8% in the control group,the difference was not statistically significant （P 〉 0.05）.The incidence of adverse reactions of the study group was 12%,and the control group＇s also 12.0%,there was no statistically significant difference between groups （P ~ 0.05）. Conclusion There was no significant difference between Ti Gray Lo and clopidogrel in the clinical use of coronary intervention,and there was no significant difference in the incidence of cardiovascular adverse events （MACE）.There were no＇significant differences in the adverse effects of bleeding,but 1 cases of dyspnea were observed in Grillo.
出处
《中国医药科学》
2017年第12期39-41,89,共4页
China Medicine And Pharmacy
关键词
替格瑞洛
氯吡格雷
冠脉介入治疗
临床疗效
安全性
Grillo
Clopidogrel
Percutaneous coronary intervention
Clinical efficacy
Safety
